DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization […]
First-in-class TDP-43 antibody developed using SurpraAntigen™ platformThe only TDP-43 antibody with reported in vivo activityLAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) […]